Hypogonadism Clinical Trials

Find Hypogonadism Clinical Trials Near You

A Single-Blind, Single-Arm, Multiple-Dose Study Evaluating the Safety and Efficacy of Testosterone Cypionate Administered Subcutaneously Via a Weekly Auto-Injector in Adult Males With Hypogonadism Through Week 24

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The goal of this Phase 3 clinical trial is to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism. The main questions it aims to answer are: * Does weekly testosterone cypionate administered using an auto-injector maintain testosterone levels within the normal range in adult males with hypogonadism? * What side effects and safety outcomes occur during treatment with testosterone cypionate auto-injector? * Is the auto-injector easy for participants to use and self-administer? All participants will receive testosterone cypionate administered subcutaneously once weekly through an auto-injector. Treatment will begin at a 75 mg weekly dose, with dose adjustments to 50 mg or 100 mg based on testosterone levels measured during the study. Participants will: * Receive weekly testosterone cypionate injections using an auto-injector for up to 52 weeks. * Attend regular clinic visits for physical examinations, laboratory tests, blood pressure monitoring, and safety assessments. * Provide blood samples to measure testosterone and other hormone levels and evaluate pharmacokinetics. * Complete questionnaires related to symptoms, quality of life, and ease of use of the auto-injector. * Record self-administration and treatment compliance in a study diary. This study will enroll adult males aged 18 to 75 years with hypogonadism and low testosterone concentrations to evaluate treatment through Week 24, with continued safety follow-up through Week 52.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Adults assigned male at birth, aged 18 to 75 years.

• Documented diagnosis of hypogonadism (low testosterone) with at least one associated symptom, such as reduced sexual desire, erectile dysfunction, fatigue, reduced energy, loss of muscle mass, decreased body hair, or mood changes.

• Fasting morning serum total testosterone concentration below 300 ng/dL on two separate occasions, at least 72 hours apart, during screening. One additional test may be allowed if one of the initial measurements is 300 ng/dL or higher.

• Body mass index (BMI) between 18.5 and 39.9 kg/m².

• Prostate-specific antigen (PSA) level between 0 and 2.5 ng/mL for participants aged 50 years or younger, or between 0 and 4.0 ng/mL for participants older than 50 years.

• Willingness to use effective contraception throughout the study and for 30 days after the last dose of study medication.

• Low-density lipoprotein (LDL) cholesterol below 190 mg/dL.

• Hemoglobin level of 16 g/dL or lower for participants without previous testosterone replacement therapy, or 17 g/dL or lower for participants who received testosterone replacement therapy within 30 days before screening.

• Participants with diabetes must have been on a stable antidiabetic treatment regimen for at least 4 weeks before screening and have HbA1c of 9.0% or lower, or have diabetes considered adequately controlled by the investigator.

• Participants with high cholesterol or other lipid disorders must have been on stable lipid-lowering treatment for at least 4 weeks before screening or have their condition considered adequately controlled by the investigator.

• Participants with high blood pressure must have been on stable antihypertensive treatment for at least 1 month before screening or have blood pressure considered adequately controlled by the investigator. Participants with normal blood pressure who are not receiving antihypertensive treatment are also eligible.

• Participants previously receiving testosterone replacement therapy must complete the required washout period before qualifying testosterone measurements: generally 2 weeks for oral, buccal, or transdermal treatment as specified in the protocol; 5 weeks for intramuscular testosterone; or the required interval following testosterone implants.

• Adequate venous access for collection of multiple blood samples.

• Willing and able to provide written informed consent and comply with all study procedures, treatment requirements, and scheduled visits.

Locations
United States
California
University of California (UCLA) (Site ID 111)
NOT_YET_RECRUITING
Santa Monica
Florida
Accel Research Site Alcanza Clinical Research (Site ID 103)
NOT_YET_RECRUITING
Deland
Floridian Clinical Research LLC (Site ID 101)
RECRUITING
Miami Lakes
Nebraska
Quality Research Center (Site ID 104)
RECRUITING
Omaha
New York
AccuMed Research Associates (Site ID 106)
RECRUITING
Garden City
Integrated Medical Professionals/Advanced Urology Centers of New York (Site ID 107)
NOT_YET_RECRUITING
New York
Rhode Island
Brown University (Site ID 108)
NOT_YET_RECRUITING
Providence
South Carolina
Coastal Carolina Research Center (Site ID 102)
NOT_YET_RECRUITING
North Charleston
Texas
Biobehavioral Research Center of Austin (Austin TX) (Site ID 105)
RECRUITING
Austin
Baylor College of Medicine (Site ID 109)
NOT_YET_RECRUITING
Houston
Contact Information
Primary
Janie M Gwinn, Ph.D.
Janie.Gwinn@amneal.com
+1-631-310-7392
Time Frame
Start Date: 2026-09-28
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 190
Treatments
Experimental: Testosterone Cypionate Auto-Injector (75 mg)
Participants with hypogonadism will receive testosterone cypionate injection administered subcutaneously into the abdomen once weekly using an auto-injector. All participants will initiate treatment at 75 mg once weekly.
Experimental: Testosterone Cypionate Auto-Injector (50 mg)
Participants with hypogonadism will receive testosterone cypionate injection administered subcutaneously into the abdomen once weekly using an auto-injector. All participants will initiate treatment at 75 mg once weekly. The dose may be adjusted to 50 mg based on serum total testosterone trough concentrations and protocol-defined dose titration criteria.
Experimental: Testosterone Cypionate Auto-Injector (100 mg)
Participants with hypogonadism will receive testosterone cypionate injection administered subcutaneously into the abdomen once weekly using an auto-injector. All participants will initiate treatment at 75 mg once weekly. The dose may be adjusted to100 mg based on serum total testosterone trough concentrations and protocol-defined dose titration criteria. Treatment will continue through the 24-week primary evaluation period. Participants completing Week 24 may continue once-weekly treatment with ongoing safety assessments through Week 52. The first dose will be administered by designated study personnel, followed by participant self-administration as specified in the protocol.
Related Therapeutic Areas
Sponsors
Collaborators: Avant Sante Research Center S.A. de C.V.
Leads: Amneal Pharmaceuticals, LLC

This content was sourced from clinicaltrials.gov

Similar Clinical Trials